Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective
References
- Ayoub I, Almaani S, Brodsky S et al. (2016) Revisiting medullary tophi: A link between uric acid and progressive chronic kidney disease? Clin Nephrol 85:109–113.
https://doi.org/10.5414/CN108663 - Baek CH, Kim H, Yang WS et al. (2018) Efficacy and safety of febuxostat in kidney transplant patients. Exp Clin Transplant 16:401–406.
https://doi.org/10.6002/ECT.2016.0367 - Bardin T, Nguyen QD, Tran KM et al. (2021) A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int 99:218–226.
https://doi.org/10.1016/J.KINT.2020.08.024 - Chen CJ, Tseng CC, Yen JH et al. (2018) ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study. Sci Rep 8:3137.
https://doi.org/10.1038/s41598-018-21425-7 - Chen MY, Wang AP, Wang JW et al. (2019) Coexistence of hyperuricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes. Diabetes Metab 45:557–563.
https://doi.org/10.1016/J.DIABET.2019.03.001 - Chen Q, Wang Z, Zhou J et al. (2020) Effect of urate-lowering therapy on cardiovascular and kidney outcomes: A systematic review and meta-analysis. Clin J Am Soc Nephrol 15:1576–1586.
https://doi.org/10.2215/CJN.05190420 - Chen-Xu M, Yokose C, Rai SK et al. (2019) Contemporary prevalence of gout and hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol 71:991–999.
https://doi.org/10.1002/art.40807 - Chewcharat A, Chen Y, Thongprayoon C et al. (2021) Febuxostat as a renoprotective agent for treatment of hyperuricaemia: A meta-analysis of randomised controlled trials. Intern Med J 51:752–762.
https://doi.org/10.1111/IMJ.14814 - Choi HK, Soriano LC, Zhang Y et al. (2012) Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ 344:d8190.
https://doi.org/10.1136/bmj.d8190 - Choi ST, Song JS, Kim SJ et al. (2020) The utility of the random urine uric acid-to-creatinine ratio for patients with gout who need uricosuric agents: Retrospective cross-sectional study. J Korean Med Sci 35:e95.
https://doi.org/10.3346/jkms.2020.35.E95 - Choi WJ, Hong YA, Min JW et al. (2021) The serum uric acid level is related to the more severe renal histopathology of female IgA nephropathy patients. J Clin Med 10:1885.
https://doi.org/10.3390/JCM10091885 - Curhan CG (2021) Kidney stones in adults: Uric acid nephrolithiasis. UpToDate.
https://www.uptodate.com/contents/kidney-stones-in-adults-diagnosis-and-acute-management-of-suspected-nephrolithiasis?search=kidney%20stones%20in%20adults&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 . Accessed 20 June 2023. - Dalbeth N, Choi HK, Joosten LAB et al. (2019) Gout. Nat Rev Dis Primers 5:69.
https://doi.org/10.1038/s41572-019-0115-y - Dalbeth N, Haskard DO (2005) Mechanisms of inflammation in gout. Rheumatology 44:1090–1096.
https://doi.org/10.1093/RHEUMATOLOGY/KEH640 - Dalbeth N, House ME, Aati O et al. (2015) Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: A dual energy CT study. Ann Rheum Dis 74:908–911.
https://doi.org/10.1136/ANNRHEUMDIS-2014-206397 - Ding L, Li H, Sun B et al. (2021) Elevated interleukin-37 associated with tophus and pro-inflammatory mediators in Chinese gout patients. Cytokine 141:155468.
https://doi.org/10.1016/J.CYTO.2021.155468 - Doria A, Galecki AT, Spino C et al. (2020) Serum urate lowering with allopurinol and kidney function in Type 1 diabetes. N Engl J Med 382:2493–2503.
https://doi.org/10.1056/NEJMOA1916624 - Fan S, Zhang P, Wang AY et al. (2019) Hyperuricemia and its related histopathological features on renal biopsy. BMC Nephrol 20:95.
https://doi.org/10.1186/S12882-019-1275-4 - García-Arroyo FE, Gonzaga G, Muñoz-Jiménez I et al. (2018) Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One 13:0202901.
https://doi.org/10.1371/JOURNAL.PONE.0202901 - Gnemmi V, Li Q, Ma Q et al. (2022) Asymptomatic hyperuricemia promotes recovery from ischemic organ injury by modulating the phenotype of macrophages. Cells 11:626.
https://doi.org/10.3390/CELLS11040626 - Gonzalez-Martin G, Cano J, Carriazo S et al. (2020) The dirty little secret of urate-lowering therapy: Useless to stop chronic kidney disease progression and may increase mortality. Clini Kidney J 13:936–947.
https://doi.org/10.1093/ckj/sfaa236 - Guan H, Zheng Y, Zhou X et al. (2020) Efficacy of different urinary uric acid indicators in patients with chronic kidney disease. BMC Nephrol 21:290.
https://doi.org/10.1186/S12882-020-01953-Z - Hare JM, Johnson RJ (2003) Uric acid predicts clinical outcomes in heart failure: Insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107: 1951–1953.
https://doi.org/10.1161/01.CIR.0000066420.36123.35 - Howard RG, Pillinger MH, Gyftopoulos S et al. (2011) Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: Concordance between readers. Arthritis Care Res 63:1456–1462.
https://doi.org/10.1002/acr.20527 - Hsu YSO, Wu IW, Chang SH et al. (2020) Comparative renoprotective effect of febuxostat and allopurinol in predialysis stage 5 chronic kidney disease patients: A nationwide database analysis. Clin Pharmacol Ther 107:1159–1169.
https://doi.org/10.1002/CPT.1697 - Hu Y, Shi Y, Chen H et al. (2022) Blockade of autophagy prevents the progression of hyperuricemic nephropathy through inhibiting NLRP3 inflammasome-mediated pyroptosis. Front Immunol 13:858494.
https://doi.org/10.3389/FIMMU.2022.858494 - Huls M, Brown CD, Windass AS et al. (2008) The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73:220–225.
https://doi.org/10.1038/SJ.KI.5002645 - Ichida K, Matsuo H, Takada T et al. (2012) Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3:764.
https://doi.org/10.1038/ncomms1756 - Jing J, Ekici AB, Sitter T et al. (2018) Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease. Sci Rep 8:13184.
https://doi.org/10.1038/S41598-018-31282-Z - Johnson RJ, Bakris GL, Borghi C et al. (2018) Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis 71:851–865.
https://doi.org/10.1053/J.AJKD.2017.12.009 - Kang DH, Nakagawa T, Feng L et al. (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897.
https://doi.org/10.1097/01.ASN.0000034910.58454.FD - Kataoka H, Mochizuki T, Ohara M et al. (2022) Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study. Sci Rep 12:3784.
https://doi.org/10.1038/S41598-022-07737-9 - Kawamura Y, Nakaoka H, Nakayama A et al. (2019) Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. Ann Rheum Dis 78:1430–1437.
https://doi.org/10.1136/annrheumdis-2019-215521 - Kim SH, Lee SY, Kim JM et al. (2020) Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis. Korean J Intern Med 35:998–1003.
https://doi.org/10.3904/KJIM.2018.423 - Konta T, Ichikawa K, Kawasaki R et al. (2020) Association between serum uric acid levels and mortality: A nationwide community-based cohort study. Sci Rep 10:6066.
https://doi.org/10.1038/S41598-020-63134-0 - Köttgen A, Hwang SJ, Larson MG et al. (2010) Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 21:337–344.
https://doi.org/10.1681/ASN.2009070725 - Li F, Guo H, Zou J et al. (2021) Clinical classification of hyperuricemia in patients with chronic kidney disease. Int Urol Nephrol 53:1665–1674.
https://doi.org/10.1007/S11255-020-02754-X - Liang X, Liu X, Li D et al. (2022) Effectiveness of urate-lowering therapy for renal function in patients with chronic kidney disease: A meta-analysis of randomized clinical trials. Front Pharmacol 13:798150.
https://doi.org/10.3389/fphar.2022.798150 - Lin TC, Hung LY, Chen YC et al. (2019) Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine 98:e16311.
https://doi.org/10.1097/MD.0000000000016311 - Liu B, Zhao L, Yang Q et al. (2021b) Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy. Int Urol Nephrol 53:2321–2332.
https://doi.org/10.1007/s11255-021-02844-4 - Liu L, Xue Y, Zhu Y et al. (2016) Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout. Arthritis Res Ther 18:268.
https://doi.org/10.1186/S13075-016-1167-Y - Liu N, Wang L, Yang T et al. (2015) EGF receptor inhibition alleviates hyperuricemic nephropathy. J Am Soc Nephrol 26:2716–2729.
https://doi.org/10.1681/ASN.2014080793 - Liu S, Liu Y, Wu X et al. (2023) Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology. J Orthop Surg Res 18:769.
https://doi.org/10.1186/S13018-023-04240-3 - Liu X, Qiu Y, Li D et al. (2021a) Effectiveness of drug treatments for lowering uric acid on renal function in patients with chronic kidney disease and hyperuricemia: A network meta-analysis of randomized controlled trials. Front Pharmacol 12:690557.
https://doi.org/10.3389/fphar.2021.690557 - Liu X, Zhai T, Ma R et al. (2018b) Effects of uric acid-lowering therapy on the progression of chronic kidney disease: A systematic review and meta-analysis. Ren Fail 40:289–297.
https://doi.org/10.1080/0886022X.2018.1456463 - Liu Y, Goldfarb DS, El-Achkar TM et al. (2018a) Tamm–Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. Am J Physiol Renal Physiol 314:F1062–F1076.
https://doi.org/10.1152/ajprenal.00233.2017 - Lu J, Dalbeth N, Yin H et al. (2019) Mouse models for human hyperuricaemia: A critical review. Nat Rev Rheumatol 15:413–426.
https://doi.org/10.1038/S41584-019-0222-X - Luo Q, Cai Y, Zhao Q et al. (2022) Effects of allopurinol on renal function in patients with diabetes: A systematic review and meta-analysis. Ren Fail 44:806–814.
https://doi.org/10.1080/0886022X.2022.2068443 - Luo Y, Song Q, Li J et al. (2024) Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: A systematic review and meta-analysis. BMC Nephrol 25:63.
https://doi.org/10.1186/S12882-024-03491-4 - Major TJ, Topless RK, Dalbeth N et al. (2018) Evaluation of the diet wide contribution to serum urate levels: Meta-analysis of population based cohorts. BMJ 363:k3951.
https://doi.org/10.1136/BMJ.K3951 - Maloberti A, Mengozzi A, Russo E et al. (2023) The results of the URRAH (Uric Acid Right for heart Health) project: A focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation. High Blood Press Cardiovasc Prev 30:411–425.
https://doi.org/10.1007/S40292-023-00602-4 - Matsuo H, Tsunoda T, Ooyama K et al. (2016a) Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. Sci Rep 6:31003.
https://doi.org/10.1038/srep31003 - Matsuo H, Yamamoto K, Nakaoka H et al. (2016b) Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis 75:652–659.
https://doi.org/10.1136/ANNRHEUMDIS-2014-206191 - Merriman T (2024) Pathophysiology of gout. UpToDate.
https://www.uptodate.com/contents/pathophysiology-of-gout#H244423514 . Accessed 20 June 2023. - Moe OW (2010) Posing the question again: Does chronic uric acid nephropathy exist? J Am Soc Nephrol 21:395–397.
https://doi.org/10.1681/ASN.2008101115 - Mount BD (2023) Asymptomatic hyperuricemia. UpToDate.
https://www.uptodate.com/contents/asymptomatic-hyperuricemia?search=asymptomatic%20hyperuricemia&source=search_result&selectedTitle=1%7E18&usage_type=default&display_rank=1#H817689 . Accessed 20 June 2023. - Nakayama A, Nakatochi M, Kawamura Y et al. (2020) Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Ann Rheumatic Dis 79:657–665.
https://doi.org/10.1136/annrheumdis-2019-216644 - Narang RK, Vincent Z, Phipps-Green A et al. (2019) Population-specific factors associated with fractional excretion of uric acid. Arthritis Res Ther 21:234.
https://doi.org/10.1186/S13075-019-2016-6 - Natsuko PD, Laura SC, Denise CC et al. (2022) Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: A case-control study. Eur J Med Res 27:62.
https://doi.org/10.1186/S40001-022-00684-1 - Pak J, Pu Y, Zhang ZT et al. (2001) Tamm–Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276: 9924–9930.
https://doi.org/10.1074/JBC.M008610200 - Pawar A, Desai RJ, Liu J et al. (2021) Updated assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. J Am Heart Assoc 10:e020045.
https://doi.org/10.1161/JAHA.120.020045 - Peng YL, Tain YL, Lee CT et al. (2020) Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep 10:10734.
https://doi.org/10.1038/S41598-020-67026-1 - Perez-Ruiz F, Calabozo M, Erauskin GG et al. (2002) Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 47:610–613.
https://doi.org/10.1002/ART.10792 - Perrenoud L, Kruse NT, Andrews E et al. (2020) Uric acid lowering and biomarkers of kidney damage in CKD Stage 3: A post hoc analysis of a randomized clinical trial. Kidney Med 2:155–161.
https://doi.org/10.1016/J.XKME.2019.11.007 - Piani F, Johnson RJ (2021) Does gouty nephropathy exist, and is it more common than we think? Kidney Int 99:31–33.
https://doi.org/10.1016/J.KINT.2020.10.015 - Pineda C, Amezcua-Guerra LM, Solano C et al. (2011) Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: An ultrasound controlled study. Arthritis Res Ther 13:R4.
https://doi.org/10.1186/AR3223 - Pisaniello HL, Fisher MC, Farquhar H et al. (2021) Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Arthritis Res Ther 23:130.
https://doi.org/10.1186/S13075-021-02416-Y - Ponticelli C, Podestà MA, Moroni G (2020) Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int 98:1149–1159.
https://doi.org/10.1016/J.KINT.2020.05.056 - Russo E, Drovandi S, Salvidio G et al. (2020) Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy. Nutr Metab Cardiovasc Dis 30:2343–2350.
https://doi.org/10.1016/J.NUMECD.2020.07.038 - Sakiyama M, Matsuo H, Shimizu S et al. (2016) The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep 6:20148.
https://doi.org/10.1038/srep20148 - Sánchez-Briales P, Marques Vidas M, López-Sánchez P et al. (2024) The uricosuric effect of SGLT2 inhibitors is maintained in the long term in patients with chronic kidney disease and Type 2 diabetes mellitus. J Clin Med 13:1360.
https://doi.org/10.3390/JCM13051360 - Sapankaew T, Thadanipon K, Ruenroengbun N et al. (2022) Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: Systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol 23:223.
https://doi.org/10.1186/S12882-022-02850-3 - Sato Y, Feig DI, Stack AG et al. (2019) The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol 15:767–775.
https://doi.org/10.1038/S41581-019-0174-Z - Schauer C, Janko C, Munoz LE et al. (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 20:511–517.
https://doi.org/10.1038/nm.3547 - Scherberich JE, Gruber R, Nockher WA et al. (2018) Serum uromodulin-a marker of kidney function and renal parenchymal integrity. Nephrol Dial Transplantat 33:284–295.
https://doi.org/10.1093/ndt/gfw422 - Sellmayr M, Hernandez Petzsche MR, Ma Q et al. (2020) Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol 31:2773–2792.
https://doi.org/10.1681/ASN.2020040523 - Sharma G, Dubey A, Nolkha N et al. (2021) Hyperuricemia, urate-lowering therapy, and kidney outcomes: A systematic review and meta-analysis. Ther Adv Musculoskeletal Dis 13:1759720X211016661.
https://doi.org/10.1177/1759720X211016661 - Shen L, Dong H, Guo Z et al. (2021a) Identification of abnormal proteins in plasma from gout patients by LC-MS/MS. Separations 8:85.
https://doi.org/10.3390/separations8060085 - Shen X, Wang C, Liang N et al. (2021b) Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout. Arthritis Rheumatol 73:1738–1748.
https://doi.org/10.1002/art.41733 - Stack AG, Dronamraju N, Parkinson J et al. (2021) Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with Type 2 diabetes: A randomized trial. Am J Kidney Dis 77:481–489.
https://doi.org/10.1053/J.AJKD.2020.09.009 - Thomas D, Gazouli M, Karantanos T et al. (2014) Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease. World J Gastroenterol 20:3609–3614.
https://doi.org/10.3748/wjg.v20.i13.3609 - Tien YY, Shih MC, Tien CP et al. (2022) To treat or not to treat? Effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: A systematic review and network meta-analysis. J Am Board Fam Med 35:140–151.
https://doi.org/10.3122/jabfm.2022.01.210273 - Tin A, Marten J, Halperin Kuhns VL et al. (2019) Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet 51:1459–1474.
https://doi.org/10.1038/S41588-019-0504-X - Tsukamoto S, Okami N, Yamada T et al. (2022) Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: A systematic review and network meta-analysis. Clin Rheumatol 41:911–919.
https://doi.org/10.1007/S10067-021-05956-5 - Ulutaş F, Bozdemir A, Çelikyürek NA et al. (2021) Cut-off value of serum uric acid for development of gout disease in patients with multiple co-morbidities. Mediterr J Rheumatol 32:243–248.
https://doi.org/10.31138/mjr.32.3.243 - Wen CC, Yee SW, Liang X et al. (2015) Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther 97:518–525.
https://doi.org/10.1002/CPT.89 - White WB, Saag KG, Becker MA et al. (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200–1210.
https://doi.org/10.1056/NEJMoa1710895 - Wu B, Chen L, Xu Y et al. (2022) The effect of allopurinol on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis. Kidney Blood Press Res 47:291–299.
https://doi.org/10.1159/000522248 - Wu CH, Yang CC, Chang HW et al. (2019) Urinary uromodulin/creatinine ratio as a potential clinical biomarker for chronic kidney disease patients with gout: A pilot study. Med Princ Pract 28:273–279.
https://doi.org/10.1159/000496844 - Wu N, Xia J, Chen S et al. (2021) Serum uric acid and risk of incident chronic kidney disease: A national cohort study and updated meta-analysis. Nutr Metab 18:94.
https://doi.org/10.1186/S12986-021-00618-4 - Wu TH, Li KJ, Yu CL et al. (2018) Tamm–Horsfall protein is a potent immunomodulatory molecule and a disease biomarker in the urinary system. Molecules 23:200.
https://doi.org/10.3390/molecules23010200 - Xiao Y, Zhang C, Zeng X et al. (2020) Microecological treatment of hyperuricemia using Lactobacillus from pickles. BMC Microbiol 20:195.
https://doi.org/10.1186/S12866-020-01874-9 - Yang AY (2020) Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther 58:21–28.
https://doi.org/10.5414/CP203466 - Yang XH, Zhang BL, Cheng Y et al. (2024) Febuxostat provides renoprotection in patients with hyperuricemia or gout: A systematic review and meta-analysis of randomized controlled trials. Ann Med 56:2332956.
https://doi.org/10.1080/07853890.2024.2332956 - Yip ASY, Leong S, Teo YH et al. (2022) Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: A systematic review and meta-regression of 43 randomized controlled trials. Ther Adv Chronic Dis 13:20406223221083509.
https://doi.org/10.1177/20406223221083509 - Yu X, Gu M, Zhu Y et al. (2022) Efficacy of urate-lowering therapy in patients with chronic kidney disease: A network meta-analysis of randomized controlled trials. Clin Ther 44:723–735.e6.
https://doi.org/10.1016/j.clinthera.2022.03.014 - Zeng XX, Tang Y, Hu K et al. (2018) Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: A meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine (Baltimore) 97:e0161.
https://doi.org/10.1097/MD.0000000000010161 - Zhang L, An K, Mou X et al. (2022) Effect of urate-lowering therapy on the progression of kidney function in patients with asymptomatic hyperuricemia: A systematic review and meta-analysis. Front Pharmacol 12:795082.
https://doi.org/10.3389/FPHAR.2021.795082/FULL - Zheng Q, Keliang W, Hongtao Q et al. (2022) Genetic association between SLC22A12 variants and susceptibility to hyperuricemia: A meta-analysis. Genetic Test Mol Biomarkers 26:81–95.
https://doi.org/10.1089/GTMB.2021.0175 - Zhu B, Yu DR, Lv JC et al. (2018) Uric acid as a predictor of immunoglobulin A nephropathy progression: A cohort study of 1965 cases. Am J Nephrol 48:127–136.
https://doi.org/10.1159/000489962 - Zhu F, Feng D, Zhang T et al. (2019) Altered uric acid metabolism in isolated colonic Crohn’s disease but not ulcerative colitis. J Gastroenterol Hepatol 34:154–161.
https://doi.org/10.1111/jgh.14356
DOI: https://doi.org/10.2478/aite-2024-0024 | Journal eISSN: 1661-4917
Language: English
Submitted on: Jun 11, 2024
Accepted on: Oct 18, 2024
Published on: Nov 29, 2024
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Related subjects:
© 2024 Barbara Moszczuk, Katarzyna Życińska, Krzysztof Mucha, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.